92549-67-2

Usage

Uses

Used in Chemical Synthesis:
2,2-Bis(4-hydroxyphenyl)-propanoic acid is used as an intermediate in the synthesis of 2,2-Bis(4-hydroxyphenyl)propanol (B447360), which is a metabolite of bisphenol A (B519495). This application is crucial for the production of various chemical compounds and pharmaceuticals.
Used in Endocrine Disruption Research:
As an endocrine disruptor, 2,2-Bis(4-hydroxyphenyl)-propanoic acid is utilized in research to understand the effects of such compounds on the hormonal system. This knowledge is vital for developing strategies to mitigate the impact of endocrine disruptors on human health and the environment.

InChI:InChI=1/C15H14O4/c1-15(14(18)19,10-2-6-12(16)7-3-10)11-4-8-13(17)9-5-11/h2-9,16-17H,1H3,(H,18,19)

Upstream product

• 7647-01-0 hydrogenchloride 
• 64-19-7 acetic acid 
• 127-17-3 2-oxo-propionic acid 
• 108-95-2 phenol 

Downstream Products

• 90138-78-6 methyl 2,2-bis(4-hydroxyphenyl)propionate 
• 120665-63-6 β-N,N-diethylaminoethyl-2,2-bis-(4-hydroxyphenyl)propionate 
• 120637-93-6 β-(N,N-Diethylamino)ethyl 2,2-Bis(4-{[(dimethylamino)carbonyl]oxy}phenyl)propionate 
• 120637-92-5 β-(N,N-Diethylamino)ethyl 2-(4-Hydroxyphenyl)-2-(4-{[(dimethylamino)carbonyl]oxy}phenyl)propionate 

Relevant academic research and scientific papers

Pd(II)-catalyzed enantioselective C-H olefination of diphenylacetic acids

(Chemical Equation Presented) Pd(II)-catalyzed enantioselective C-H olefination of diphenylacetic acid substrates has been achieved through the use of monoprotected chiral amino acid ligands. The absolute configuration of the resulting olefinated products

Symmetrical bis(heteroarylmethoxyphenyl)alkylcarboxylic acids as inhibitors of leukotriene biosynthesis

Symmetrical bis(quinolylmethoxyphenyl)alkylcarboxylic acids were investigated as inhibitors of leukotriene biosynthesis and 4,4-bis(4-(2-quinolylmethoxy)phenyl)pentanoic acid sodium salt (47·Na) met our design parameters for a drug candidate (ABT-080). This compound was readily synthesized in three steps from commercially available diphenolic acid. Against intact human neutrophils, 47·Na inhibited ionophore-stimulated LTB4 formation with an IC50 = 20 nM. In zymosan-stimulated mouse peritoneal macrophages producing both LTC4 and PGE2, 47·Na showed 9000-fold selectivity for inhibition of LTC4 (IC50 = 0.16 nM) over PGE2 (IC50 = 1500 nM). Preliminary pharmacokinetic evaluation in rat and cynomolgus monkey demonstrated good oral bioavailability and elimination half-lives of 9 and 5 h, respectively. Pharmacological evaluation of leukotriene inhibition with oral dosing was demonstrated in a rat pleural inflammation model (ED50 = 3 mg/kg) and a rat peritoneal passive anaphylaxis model (LTB4, ED50 = 2.5 mg/kg; LTE4, ED50 = 1.0 mg/kg). In a model of airway constriction induced by antigen challenge in actively sensitized guinea pigs, 47·Na dosed orally blocked bronchoconstriction with an ED50 = 0.4 mg/kg, the most potent activity we have observed for any leukotriene inhibitor in this model. The mode of inhibitory action of 47·Na occurs at the stage of 5-lipoxygenase biosynthesis as it blocks both leukotriene pathways leading to LTB4 and LTC4 but not PGH2 biosynthesis. However, 47·Na does not inhibit 5-lipoxygenase catalysis in a broken cell enzyme assay; therefore it is likely that 47·Na acts as a FLAP inhibitor.

Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis

Compounds having the formula: STR1 wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally